Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Gould

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
BMJ (Clinical Research Ed.)|July 6, 2002
Predictors of poor outcome and benefits from antibiotics in children with acute otitis media: pragmatic randomised trialPaul Little, Clare Gould, Michael Moore, et al.
Pathology|February 27, 2024
Observations from a national sample exchange program for molecular haematology testingClare Gould, Michelle McBean, Ella Thompson, et al.
Pathology|December 16, 2025
Advancing diagnostic targeted RNA sequencing for haematological malignancies within an Australian sample exchange programEric Wenlong Li, Ing-Soo Tiong, Clare Gould, et al.
European Journal of Haematology|June 19, 2019
The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphomaColm Keane, Joshua Tobin, Jay Gunawardana, et al.
Blood|February 17, 2018
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCLFrank Vari, David Arpon, Colm Keane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell LymphomaColm Keane, Clare Gould, Kimberley Jones, et al.
Oncotarget|November 10, 2018
Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphomaQingyan Cui, Frank Vari, Alexandre S Cristino, et al.
The Lancet. Haematology|December 22, 2015
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based studyColm Keane, Frank Vari, Mark Hertzberg, et al.
British Journal of Haematology|August 24, 2021
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic targetClare Gould, Jennifer Lickiss, Yamuna Kankanige, et al.
Blood Advances|July 10, 2019
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter studyAllison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
BMJ (Clinical Research Ed.)|July 6, 2002
Predictors of poor outcome and benefits from antibiotics in children with acute otitis media: pragmatic randomised trialPaul Little, Clare Gould, Michael Moore, et al.
Pathology|February 27, 2024
Observations from a national sample exchange program for molecular haematology testingClare Gould, Michelle McBean, Ella Thompson, et al.
Pathology|December 16, 2025
Advancing diagnostic targeted RNA sequencing for haematological malignancies within an Australian sample exchange programEric Wenlong Li, Ing-Soo Tiong, Clare Gould, et al.
European Journal of Haematology|June 19, 2019
The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphomaColm Keane, Joshua Tobin, Jay Gunawardana, et al.
Blood|February 17, 2018
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCLFrank Vari, David Arpon, Colm Keane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell LymphomaColm Keane, Clare Gould, Kimberley Jones, et al.
Oncotarget|November 10, 2018
Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphomaQingyan Cui, Frank Vari, Alexandre S Cristino, et al.
The Lancet. Haematology|December 22, 2015
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based studyColm Keane, Frank Vari, Mark Hertzberg, et al.
British Journal of Haematology|August 24, 2021
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic targetClare Gould, Jennifer Lickiss, Yamuna Kankanige, et al.
Blood Advances|July 10, 2019
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter studyAllison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, et al.
Pageof 2